Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · April 25, 2023

Enzalutamide ± Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial)
J. Clin. Oncol 2023 Mar 30;[EPub Ahead of Print], MJ Morris, G Heller, DW Hillman, O Bobek, C Ryan, ES Antonarakis, AH Bryce, O Hahn, H Beltran, AJ Armstrong, L Schwartz, LD Lewis, JH Beumer, B Langevin, EC McGary, PT Mehan, A Goldkorn, BJ Roth, H Xiao, C Watt, ME Taplin, S Halabi, EJ Small

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading